Immunology

  1. A rapidly adaptable biomaterial vaccine for SARS-CoV-2

    1. Fernanda Langellotto
    2. Benjamin T. Seiler
    3. Jingyou Yu
    4. Mark J. Cartwright
    5. Des White
    6. Chyenne Yeager
    7. Michael Super
    8. Edward J. Doherty
    9. Dan H. Barouch
    10. David J. Mooney

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Animal Model Prescreening: Pre-exposure to SARS-CoV-2 impacts responses in the NHP model

    1. Keersten M. Ricks
    2. Andrew S. Herbert
    3. Jeffrey W. Koehler
    4. Paul A. Kuehnert
    5. Tamara L. Clements
    6. Charles J. Shoemaker
    7. Ana I. Kuehne
    8. Cecilia M. O’Brien
    9. Susan R. Coyne
    10. Korey L. Delp
    11. Kristen S. Akers
    12. John M. Dye
    13. Jay W. Hooper
    14. Jeffrey M. Smith
    15. Jeffrey R. Kugelman
    16. Brett F. Beitzel
    17. Kathleen M. Gibson
    18. Sara C. Johnston
    19. Timothy D. Minogue

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains

    1. Tongqing Zhou
    2. Yaroslav Tsybovsky
    3. Adam S. Olia
    4. Jason Gorman
    5. Micah A. Rapp
    6. Gabriele Cerutti
    7. Gwo-Yu Chuang
    8. Phinikoula S. Katsamba
    9. Alexandra Nazzari
    10. Jared M. Sampson
    11. Arne Schon
    12. Pengfei D. Wang
    13. Jude Bimela
    14. Wei Shi
    15. I-Ting Teng
    16. Baoshan Zhang
    17. Jeffrey C. Boyington
    18. Mallika Sastry
    19. Tyler Stephens
    20. Jonathan Stuckey
    21. Shuishu Wang
    22. Richard A. Friesner
    23. David D. Ho
    24. John R. Mascola
    25. Lawrence Shapiro
    26. Peter D. Kwong

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays

    1. Mei San Tang
    2. James Brett Case
    3. Caroline E. Franks
    4. Rita E. Chen
    5. Neil W. Anderson
    6. Jeffrey P. Henderson
    7. Michael S. Diamond
    8. Ann M. Gronowski
    9. Christopher W. Farnsworth

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine

    1. Flavia Chiuppesi
    2. Marcela d’Alincourt Salazar
    3. Heidi Contreras
    4. Vu H Nguyen
    5. Joy Martinez
    6. Soojin Park
    7. Jenny Nguyen
    8. Mindy Kha
    9. Angelina Iniguez
    10. Qiao Zhou
    11. Teodora Kaltcheva
    12. Roman Levytskyy
    13. Nancy D Ebelt
    14. Tae Hyuk Kang
    15. Xiwei Wu
    16. Thomas Rogers
    17. Edwin R Manuel
    18. Yuriy Shostak
    19. Don J Diamond
    20. Felix Wussow

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

    1. Alan Bénard
    2. Anne Jacobsen
    3. Maximilian Brunner
    4. Christian Krautz
    5. Bettina Klösch
    6. Izabela Swierzy
    7. Elisabeth Naschberger
    8. Torsten Birkholz
    9. Ixchel Castellanos
    10. Denis Trufa
    11. Horia Sirbu
    12. Marcel Vetter
    13. Andreas E. Kremer
    14. Kai Hildner
    15. Andreas Hecker
    16. Fabian Edinger
    17. Matthias Tenbusch
    18. Enrico Richter
    19. Hendrik Streeck
    20. Marc M. Berger
    21. Thorsten Brenner
    22. Markus A. Weigand
    23. Filip K. Swirski
    24. Georg Schett
    25. Robert Grützmann
    26. Georg F. Weber

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis

    1. Onyeka S. Chukwudozie
    2. Rebecca C. Chukwuanukwu
    3. Iroanya O. Onyekachi
    4. Eze M. Daniel
    5. Duru C. Vincent
    6. Dele-Alimi T. Onaopemipo
    7. Busuyi D. Kehinde
    8. Bankole T. Taiwo
    9. Obi C. Perpetua
    10. Okinedo U. Elizabeth

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Early data on the performance of a combined SARS-CoV-2 spike-nucleocapsid antibody lateral flow device compared to a nucleocapsid-only device

    1. Christian A. Linares
    2. Felicity Ryan
    3. Samuel E. Moses

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronaviruses

    1. Ulrik Stervbo
    2. Sven Rahmann
    3. Toralf Roch
    4. Timm H. Westhof
    5. Nina Babel

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies

    1. Priyamvada Acharya
    2. Wilton Williams
    3. Rory Henderson
    4. Katarzyna Janowska
    5. Kartik Manne
    6. Robert Parks
    7. Margaret Deyton
    8. Jordan Sprenz
    9. Victoria Stalls
    10. Megan Kopp
    11. Katayoun Mansouri
    12. Robert J Edwards
    13. R. Ryan Meyerhoff
    14. Thomas Oguin
    15. Gregory Sempowski
    16. Kevin Saunders
    17. Barton F. Haynes

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 34 of 174 Next